XBIT - NASDAQ
XBiotech Inc.
$2.39
-0.27%XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.
At a Glance
Live SnapshotXBiotech Inc. Management Team
Dr. Sushma Shivaswamy Ph.D.
Chief Scientific Officer
Compensation
$657,572
Ms. Angela Hu
Director of Finance
Compensation
$285,419
Mr. John Simard
Founder, President, Chief Executive Officer & Chairman
Compensation
$6,245,581
XBiotech Inc. Insider Positioning
During the last 12 months, there has been no insider trading activity reported for XBIT.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
No insider trading activity reported. This could indicate blackout periods, lack of conviction, or regulatory restrictions.
Insider Participation
No insider trading activity reported from any insiders in the past year.
SEC Filings
XBIT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | July 07, 2025 | August 29, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | May 01, 2024 | June 20, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 28, 2023 | June 23, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | May 13, 2022 | June 22, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 29, 2021 | June 22, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 29, 2020 | June 26, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 30, 2019 | June 19, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 30, 2018 | April 30, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 28, 2017 | June 19, 2017 | 2017 | |
DEF 14A DEF 14A 2016 N/A | April 29, 2016 | June 20, 2016 | 2016 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.